Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Non Operating Income (2017 - 2025)

VYNE Therapeutics' Non Operating Income history spans 9 years, with the latest figure at $1.8 million for Q2 2025.

  • For Q2 2025, Non Operating Income rose 79.32% year-over-year to $1.8 million; the TTM value through Jun 2025 reached $4.1 million, up 36.88%, while the annual FY2025 figure was $3.0 million, 21.31% down from the prior year.
  • Non Operating Income reached $1.8 million in Q2 2025 per VYNE's latest filing, up from $594000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.8 million in Q2 2025 to a low of -$69000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $435388.9, with a median of $249500.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: crashed 112.59% in 2021, then skyrocketed 8866.67% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $26000.0 in 2021, then surged by 807.69% to $236000.0 in 2022, then soared by 188.14% to $680000.0 in 2023, then rose by 11.76% to $760000.0 in 2024, then surged by 136.18% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Non Operating Income are $1.8 million (Q2 2025), $594000.0 (Q1 2025), and $760000.0 (Q4 2024).